Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section updated to add new study sites across the United States, Australia, Canada, and several European regions, and older location entries were removed. The revision also includes a new version tag (v3.3.3).SummaryDifference1%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not relate to the study; updated the page revision to v3.3.2.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page no longer displays the government funding status notice that warned information may be out of date and directed users to operating-status pages. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedMinor updates on the Study Details page, including the latest update timestamp and a new publication reference. No changes to study design, eligibility criteria, endpoints, or patient-facing information.SummaryDifference0.3%

- Check91 days agoChange DetectedSummary: The page now displays a funding-status notice and an updated version tag (v3.2.0) while removing the old version tag (v3.1.0).SummaryDifference3%

- Check99 days agoChange DetectedPage updated to version v3.1.0 and adds information about B-cell lymphoma; previous version tag v3.0.2 is removed.SummaryDifference0.1%

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.